miR-223在心血管疾病中的研究进展与挑战

Research Advances and Challenges of miR-223 in Cardiovascular Disease

  • 摘要: 心血管疾病(cardiovascular disease, CVD)是目前危害人类健康的最严重疾病之一,包括心肌缺血综合征、心肌纤维化、房颤等疾病。微RNA(microRNAs,miRNAs/miR)是一类小分子非编码RNA,通过与特定序列结合,进而调控转录后加工、翻译或表观遗传修饰等过程,从而调节基因表达。研究发现,miR-223与多种CVD的发生发展相关,是有潜力的特异性治疗靶点。本文以心肌缺血综合征、心肌纤维化以及房颤为切入点,总结miR-223在CVD中的相关研究,探讨其作为特异性治疗靶点的应用前景和面临的挑战,为CVD的诊治提供新思路。

     

    Abstract: Cardiovascular disease (CVD) is currently one of the most severe diseases endangering human health, encompassing myocardial ischemia syndrome, myocardial fibrosis, atrial fibrillation, and other conditions. MicroRNAs (miRNAs/miR) are a class of small non-coding RNAs that can bind to specific sequences and subsequently regulate post-transcriptional processing, translation, or epigenetic modifications, thereby modulating gene expression. Studies have found that miR-223 is associated with the occurrence and development of CVD and represents a potential specific therapeutic target. This article summarizes the relevant research on miR-223 in CVD, focusing on myocardial ischemia syndrome, myocardial fibrosis, and atrial fibrillation, and discusses its application prospects and challenges as a specific therapeutic target, providing new ideas for the diagnosis and treatment of CVD.

     

/

返回文章
返回